Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033

Pfizer

Overview

The purpose of this study is to determine whether fenofibrate effects the toleration, safety, or efficacy biomarkers of CP-742,033, a drug being developed for the treatment of obesity.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Conditions

Obesity

Interventions

CP-742,033DRUG

FenofibrateDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * BMI of 30-40 kg/m2 Exclusion Criteria: * Women of childbearing potential

Outcomes

Primary Outcomes

Toleration and safety

Secondary Outcomes

Efficacy biomarkers, serum lipids

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.